Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Debdulal Chakraborty, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Saptorshi Majumdar, Ranabir Bhattacharya & Ritobroto Maitra. (2023) Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence. Clinical Ophthalmology 17, pages 1067-1076.
Read now
Read now
Brian L. VanderBeek, Yinxi Yu, Neal Oden, Paul VanVeldhuisen, Barbara Blodi, Michael Ip & Ingrid U. Scott. (2023) Visit Adherence and Visual Acuity in Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2). Ophthalmic Epidemiology 0:0, pages 1-6.
Read now
Read now
Kai-Bo Yang, Lei Liu, Hao Feng, Jun Li, Zhe-Li Liu, He-Nan Liu & Han Zhang. (2021) Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment. Therapeutics and Clinical Risk Management 17, pages 489-496.
Read now
Read now
Bianka Sobolewska, Muhammed Sabsabi & Focke Ziemssen. (2021) Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology 15, pages 4317-4326.
Read now
Read now
João Figueira, José Henriques, Ângela Carneiro, Carlos Marques-Neves, Rita Flores, João Paulo Castro-Sousa, Angelina Meireles, Nuno Gomes, João Nascimento, Miguel Amaro & Rufino Silva. (2021) Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization. Clinical Ophthalmology 15, pages 3221-3230.
Read now
Read now
Alan R Morse & William H Seiple. (2020) Decreasing Avoidable Vision Loss: Identifying Antecedents of Adherence. Clinical Ophthalmology 14, pages 3735-3739.
Read now
Read now
Alfredo Adán, Francisco Cabrera, Marta S Figueroa, Enrique Cervera, Francisco J Ascaso, Patricia Udaondo, Maximino Abraldes, Miguel Ángel Reyes, Marta Pazos, Bernardete Pessoa & Félix Armadá. (2020) Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations. Clinical Ophthalmology 14, pages 2091-2107.
Read now
Read now
Nakhleh E Abu-Yaghi, Alaa M Abed, Dana F Khlaifat, Mohammed B Nawaiseh, Laith O Emoush, Heba Z AlHajjaj, Ala M Abojaradeh, Mariana N Hattar, Sura K Abusaleem, Hashem M Sabbagh, Yazan A Abu Gharbieh & Sura A Quaqazeh. (2020) Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients. Clinical Ophthalmology 14, pages 921-929.
Read now
Read now
Josep Callizo, Focke Ziemssen, Thomas Bertelmann, Nicolas Feltgen, Jessica Vögeler, Mirja Koch, Nicole Eter, Sandra Liakopoulos, Steffen Schmitz-Valckenberg & Georg Spital. (2019) Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study. Clinical Ophthalmology 13, pages 2167-2179.
Read now
Read now
Justus G Garweg. (2019) Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration. Clinical Ophthalmology 13, pages 1289-1295.
Read now
Read now
Clemente Capasso & Jean-Yves Winum. (2019) Novel method of treating macular degeneration: a patent evaluation (WO2018/107005). Expert Opinion on Therapeutic Patents 29:10, pages 749-752.
Read now
Read now
Articles from other publishers (71)
Anna Nowińska. (2023) Current Opinion on Long-Lasting Therapy in CI-DME. Journal of Ocular Diseases and Therapeutics 10, pages 1-10.
Crossref
Crossref
Olapeju A. Sam-Oyerinde & Praveen J. Patel. (2023) Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries. Ophthalmology and Therapy 12:2, pages 809-826.
Crossref
Crossref
John Hovanesian, I Paul Singh, Aditi Bauskar, Srilatha Vantipalli, Rabia Gurses Ozden & Michael H. Goldstein. (2023) Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy. Current Opinion in Ophthalmology 34:Supplement 1, pages S1-S13.
Crossref
Crossref
Livia Faes, Kathrin Golla, Meriam Islam, Kenny R. Lienhard, Martin K. Schmid, Dawn A. Sim & Lucas M. Bachmann. (2022) System usability, user satisfaction and long-term adherence to mobile hyperacuity home monitoring—prospective follow-up study. Eye 37:4, pages 650-654.
Crossref
Crossref
Mahmut Kaya, Taylan Öztürk, Nilüfer Koçak, Betül Akbulut Yağcı, Ferdane Ataş & Süleyman Kaynak. (2023) Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience. Turkish Journal of Ophthalmology 53:1, pages 30-36.
Crossref
Crossref
Weilin Song, Emese Kanyo, Riley Bastian, Rishi P. Singh & Aleksandra V. Rachitskaya. (2022) Visual Acuity in Patients Requiring Intravitreal Injections: Short-Term and Long-Term Effects of Delay in Care. Journal of VitreoRetinal Diseases 7:1, pages 20-26.
Crossref
Crossref
Zasim Azhar SiddiquiTrupti DhumalJay PatelTraci LeMastersArghavan AlmonyKhalid M Kamal. (2022) Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis. Journal of Managed Care & Specialty Pharmacy 28:12, pages 1350-1364.
Crossref
Crossref
A. C. S. Tan, R. Schwartz, D. Anaya, I. Chatziralli, M. Yuan, M. V. Cicinelli, L. Faes, M. Mustapha, N. Phasukkijwatana, D. Pohlmann, R. Reynolds, A. Rosenblatt, A. Savastano, S. Touhami, K. Vaezi, C. V. Ventura, D. Vogt, J. Ambati, M. D. de Smet & A. Loewenstein. (2022) Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations. International Journal of Retina and Vitreous 8:1.
Crossref
Crossref
Mirataollah Salabati, Raziyeh Mahmoudzadeh, Jae-Chiang Wong, Dillan Patel, Samir N Patel, Anthony Obeid, Arunan Sivalingam, James F Vander, Sunir J Garg, Allen C Ho, Carl D Regillo & Jason Hsu. (2022) Outcomes of eyes with retinal vein occlusion that are lost to follow-up after antivascular endothelial growth factor therapy. British Journal of Ophthalmology 106:12, pages 1742-1747.
Crossref
Crossref
Anke Schmid, Felicitas Bucher, Erika Liczenczias, Sara Maslanka Figueroa, Bettina Müller & Hansjürgen Agostini. (2022) nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey. Graefe's Archive for Clinical and Experimental Ophthalmology 260:10, pages 3241-3253.
Crossref
Crossref
Maja Vinković, Andrijana Kopić & Tvrtka Benašić. 2022. Recent Advances and New Perspectives in Managing Macular Degeneration. Recent Advances and New Perspectives in Managing Macular Degeneration.
Reinhard Angermann, Alexander Franchi, Katharina Frede, Victoria Stöckl, Christoph Palme, Martina Kralinger & Claus Zehetner. (2022) Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study. BMC Ophthalmology 22:1.
Crossref
Crossref
Yvonne T. Bui, Matthew R. Starr, Felix F. Kung, Camilo A. Mejia & Sophie J. Bakri. (2022) Long-Term Visual Outcomes in Exudative Age-Related Macular Degeneration Patients With Unanticipated Gaps in Therapy. Ophthalmic Surgery, Lasers and Imaging Retina 53:9, pages 481-489.
Crossref
Crossref
Louisa Maria Bulirsch, Marlene Saßmannshausen, Jennifer Nadal, Raffael Liegl, Sarah Thiele & Frank G Holz. (2022) Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. British Journal of Ophthalmology 106:9, pages 1288-1294.
Crossref
Crossref
Frank G. Holz, Tomohiro Iida, Ichiro Maruko & SriniVas R. Sadda. (2022) A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 42:9, pages 1629-1637.
Crossref
Crossref
Jean-Philippe Rozon, Mélanie Hébert, Carolane Laverdière, Alexandre Lachance, Serge Bourgault, Mathieu Caissie, Laurence Letartre, Eric Tourville & Ali Dirani. (2022) DELAYED FOLLOW-UP IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED UNDER UNIVERSAL HEALTH COVERAGE. Retina 42:9, pages 1693-1701.
Crossref
Crossref
Laurent Kodjikian, Francesco Bandello, Marc de Smet, Corrine Dot, Javier Zarranz-Ventura, Anat Loewenstein, Aditya Sudhalkar, Alper Bilgic, José Cunha-Vaz, Werner Dirven, Francine Behar-Cohen & Thibaud Mathis. (2022) Fluocinolone acetonide implant in diabetic macular edema: International experts’ panel consensus guidelines and treatment algorithm. European Journal of Ophthalmology 32:4, pages 1890-1899.
Crossref
Crossref
Claus von der Burchard, Helge Sudkamp, Jan Tode, Cristoph Ehlken, Konstantine Purtskhvanidze, Moritz Moltmann, Britta Heimes, Peter Koch, Michael Münst, Malte vom Endt, Timo Kepp, Dirk Theisen-Kunde, Inke König, Gereon Hüttmann & Johann Roider. (2022) Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) for neovascular age-related macular degeneration: a cross-sectional diagnostic accuracy study. BMJ Open 12:6, pages e055082.
Crossref
Crossref
Pierre-Henry Gabrielle, Vuong Nguyen, Catherine Creuzot-Garcher, Jennifer J. Arnold, Hemal Mehta, Mónica Asencio Duran, Walid Bougamha, Ester Carreño, Francesco Viola, David Squirrell, Daniel Barthelmes & Mark Gillies. (2022) THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Retina 42:6, pages 1085-1094.
Crossref
Crossref
Anke Tripp, Sarah Brink, Klaus Dieter Lemmen, Peter Mussinghoff & Daniel Pauleikhoff. (2022) Können digitale Instrumente wie die Makula-App die AMD-Therapie unterstützen?. Klinische Monatsblätter für Augenheilkunde 239:06, pages 793-798.
Crossref
Crossref
Birthe Stemplewitz, Joel Luethy, Mau-Thek Eddy, Martin Spitzer, Ulrike Brocks, Julie Kieckhoefel, Christa Schneemann, Ulrich Schaudig & Marc Schargus. (2022) Impact of the COVID-19 pandemic’s first wave on the care and treatment situation of intravitreal injections in a German metropolitan region. Graefe's Archive for Clinical and Experimental Ophthalmology 260:6, pages 1877-1886.
Crossref
Crossref
Roee Arnon, Joseph Pikkel, Tal Yahalomi, Nir Stanescu, Keren Wood, Ari Leshno, Asaf Achiron & Assaf Hilely. (2022) The negative impact of COVID-19 pandemic on age-related macular degeneration patients treated with intravitreal bevacizumab injections. International Ophthalmology 42:11, pages 3387-3395.
Crossref
Crossref
Pierre‐Henry Gabrielle, Vuong Nguyen, Sanjeeb Bhandari, Hemal Mehta, Francesco Viola, Jennifer Arnold, Samantha Fraser‐Bell, Daniel Barthelmes, Catherine Creuzot‐Garcher & Mark Gillies. (2020) Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmologica 100:3, pages 285-294.
Crossref
Crossref
Blanche L. Kuo & Rishi P. Singh. (2022) Brolucizumab for the treatment of diabetic macular edema. Current Opinion in Ophthalmology 33:3, pages 167-173.
Crossref
Crossref
Olga Karaca, Hansjürgen Agostini, Enno Bialas, Ursula Hahn, Aljoscha S. Neubauer, Jörg-Andreas Rüggeberg, Janine Subert & Focke Ziemssen. (2022) Surgical Care in Specialist Ophthalmology Departments: Structure and Impact of the COVID-19 Pandemic. Klinische Monatsblätter für Augenheilkunde.
Crossref
Crossref
Vivian Paraskevi Douglas, Konstantinos A. A. Douglas, Demetrios G. Vavvas, Joan W. Miller & John B. Miller. (2022) Short- and Long-Term Visual Outcomes in Patients Receiving Intravitreal Injections: The Impact of the Coronavirus 2019 Disease (COVID-19)—Related Lockdown. Journal of Clinical Medicine 11:8, pages 2097.
Crossref
Crossref
Christian Wolfram & Marc Schargus. (2021) Das Hamburger Register für intravitreale Injektionstherapien (QIVOM)The Hamburg register for intravitreal injection therapies (QIVOM). Der Ophthalmologe 119:3, pages 280-287.
Crossref
Crossref
Dhanashree Ratra, Krishnakanta Roy, Sneha Giridhar, Sushant Madaan, Pramod Bhende, Muna Bhende, Girish Rao, Parveen Sen, Rajiv Raman, Vikas Khetan, Chetan Rao, S. Pradeep, Vinata Muralidharan, G. Suganeswari, Rupak Roy, Debmalya Das, Suchetana Mukherjee, P. S. Rajesh, V. Jayaprakash, Eesh Nigam, C. Charanya, S. Sruthi, Maitreyi Chowdhury & Kalpita Das. (2021) Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. Ophthalmology and Therapy 11:1, pages 135-149.
Crossref
Crossref
Tso-Ting Lai, Ta-Ching Chen, Chang-Hao Yang, Chung-May Yang, Tzyy-Chang Ho & Yi-Ting Hsieh. (2022) Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study. Frontiers in Medicine 8.
Crossref
Crossref
Daniela Claessens, Parul Ichhpujani & Rohan Bir Singh. (2021) MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases. International Ophthalmology 42:1, pages 229-238.
Crossref
Crossref
Johanna J. Zirpel, Isabel B. Pfister, Christin Gerhardt & Justus G. Garweg. (2021) Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefe's Archive for Clinical and Experimental Ophthalmology 259:12, pages 3569-3578.
Crossref
Crossref
Weilin Song, Rishi P. Singh & Aleksandra V. Rachitskaya. (2021) The Effect of Delay in Care among Patients Requiring Intravitreal Injections. Ophthalmology Retina 5:10, pages 975-980.
Crossref
Crossref
Hakan Kaymak, Birte Graff, Frank Schaeffel, Achim Langenbucher, Berthold Seitz & Hartmut Schwahn. (2021) A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting. Graefe's Archive for Clinical and Experimental Ophthalmology 259:10, pages 3083-3092.
Crossref
Crossref
Arshad M. Khanani, Sunil S. Patel, Victor H. Gonzalez, Suk J. Moon, Glenn J. Jaffe, John A. Wells, Petra Kozma, Pravin U. Dugel & Raj K. Maturi. (2021) Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema. Ophthalmology Science 1:3, pages 100040.
Crossref
Crossref
Nicole Eter, Zoran Hasanbasic, Georgios Keramas, Christine Rech, Helmut Sachs, Harald Schilling, Joachim Wachtlin, Peter Wiedemann & Carsten Framme. (2021) PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 259:8, pages 2213-2223.
Crossref
Crossref
Albrecht Lommatzsch, Nicole Eter, Christoph Ehlken, Ines Lanzl, Hakan Kaymak, Alexander K. Schuster & Focke Ziemssen. (2020) Adhärenz bei der Anti-VEGF-Therapie – Überlegungen und praktische EmpfehlungenAdherence to anti-VEGF treatment—Considerations and practical recommendations. Der Ophthalmologe 118:8, pages 801-809.
Crossref
Crossref
Chad Andrews, Pradeepa Yoganathan & Jennifer A. Pereira. (2021) Blind Spots: Gaps in Disease Knowledge and the Role of Patient Education for Canadians With Diabetic Macular Edema. Canadian Journal of Diabetes 45:4, pages 375-378.
Crossref
Crossref
Claus von der Burchard, Moritz Moltmann, Jan Tode, Christoph Ehlken, Helge Sudkamp, Dirk Theisen-Kunde, Inke König, Gereon Hüttmann & Johann Roider. (2020) Self-examination low-cost full-field OCT (SELFF-OCT) for patients with various macular diseases. Graefe's Archive for Clinical and Experimental Ophthalmology 259:6, pages 1503-1511.
Crossref
Crossref
Meera S. Ramakrishnan, Yinxi Yu & Brian L. VanderBeek. (2020) Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet Protocol T. Graefe's Archive for Clinical and Experimental Ophthalmology 259:6, pages 1419-1425.
Crossref
Crossref
Rajya L Gurung, Liesel M FitzGerald, Bennet J McComish, Alex W Hewitt, Nitin Verma & Kathryn P Burdon. (2021) Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice. BMJ Open Ophthalmology 6:1, pages e000749.
Crossref
Crossref
Jamie Enoch, Arevik Ghulakhszian, David P Crabb, Christiana Dinah & Deanna J Taylor. (2021) Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study. BMJ Open 11:4, pages e049495.
Crossref
Crossref
Annika J Patel, Dante J Pieramici & Nika Bagheri. (2021) Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration. Therapeutic Delivery 12:3, pages 191-200.
Crossref
Crossref
Sam E Mansour, Daniel F Kiernan, Daniel B Roth, David Eichenbaum, Nancy M Holekamp, Samer Kaba & Erica Werts. (2021) Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. British Journal of Ophthalmology 105:3, pages 414-419.
Crossref
Crossref
Kai Rothaus, Marie-Louise Farecki, Peter Mussinghoff, Henrik Faatz, Georg Spital, Daniel Pauleikhoff & Albrecht Peter Lommatzsch. (2019) Analyse des Versorgungsmodells „Portal“ – Untersuchung der Ergebnisqualität der IVOM-Therapie im Hinblick auf Latenzzeiten bei exsudativer AMD. Klinische Monatsblätter für Augenheilkunde 238:03, pages 293-301.
Crossref
Crossref
Michelle Prasuhn, Maximilian Kurz, Salvatore Grisanti, Annekatrin Holzhey & Mahdy Ranjbar. (2021) Three-year clinical and optical coherence tomography follow-up after stereotactic radiotherapy for neovascular age-related macular degeneration. Advances in Medical Sciences 66:1, pages 215-220.
Crossref
Crossref
Mali Okada, Paul Mitchell, Robert P. Finger, Bora Eldem, S. James Talks, Ceri Hirst, Luciano Paladini, Jane Barratt, Tien Yin Wong & Anat Loewenstein. (2021) Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology 128:2, pages 234-247.
Crossref
Crossref
Marco Verolino, Piergiacomo Grassi, Gennaro Sosto, Gaetano D’Onofrio, Stefania De Simone & Ciro Costagliola. (2021) Lean approach to the management of patients undergoing intravitreal injections during COVID-19 pandemic. Therapeutic Advances in Ophthalmology 13, pages 251584142110188.
Crossref
Crossref
. (2020) Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edemaStellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makulaödems. Der Ophthalmologe 118:S1, pages 40-67.
Crossref
Crossref
Monique A. Rose, Meri Vukicevic & Konstandina Koklanis. (2020) Adherence of patients with diabetic macular oedema to intravitreal injections: A systematic review. Clinical & Experimental Ophthalmology 48:9, pages 1286-1298.
Crossref
Crossref
Lauren M. Wasser, Yishay Weill, Koby Brosh, Itay Magal, Michael Potter, Israel Strassman, Evgeny Gelman, Meni Koslowsky, David Zadok & Joel Hanhart. (2020) The Impact of COVID-19 on Intravitreal Injection Compliance. SN Comprehensive Clinical Medicine 2:12, pages 2546-2549.
Crossref
Crossref
Michael A. Singer, Charles C. Wykoff & Dilraj S. Grewal. (2020) Effects of Long-Term DME Control With 0.2 µg/Day Fluocinolone Acetonide Implant on Quality of Life: An Exploratory Analysis From the FAME Trial. Ophthalmic Surgery, Lasers and Imaging Retina 51:11, pages 658-667.
Crossref
Crossref
Tso-Ting Lai, Yi-Ting Hsieh, Chung-May Yang, Tzyy-Chang Ho & Chang-Hao Yang. (2020) EFFECT OF REIMBURSEMENT POLICY ON VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH RANIBIZUMAB. Retina 40:11, pages 2191-2197.
Crossref
Crossref
Maria Oliva Grassi, Claudio Furino, Nicola Recchimurzo, Fabio De Vitis, Giancarlo Sborgia, Luigi Sborgia, Arianna Meleleo, Teresa Molfetta, Marina Piepoli, Paolo Locatelli, Francesco Boscia & Giovanni Alessio. (2020) Implementation of Lean healthcare methodology in designing an Intravitreal Injection Center: first Italian experience. International Ophthalmology 40:10, pages 2607-2615.
Crossref
Crossref
Christoph Ehlken, Focke Ziemssen, Nicole Eter, Ines Lanzl, Hakan Kaymak, Albrecht Lommatzsch & Alexander K. Schuster. (2020) Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefe's Archive for Clinical and Experimental Ophthalmology 258:10, pages 2077-2090.
Crossref
Crossref
Kelvin Yi Chong Teo, Nakul Saxena, Alfred Gan, Tien Y. Wong, Mark C. Gillies, Usha Chakravarthy & Chui Ming Gemmy Cheung. (2020) Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina 4:9, pages 871-880.
Crossref
Crossref
Ivan Seah, Xinxin Zhao, Qianyu Lin, Zengping Liu, Steven Zheng Zhe Su, Yew Sen Yuen, Walter Hunziker, Gopal Lingam, Xian Jun Loh & Xinyi Su. (2020) Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye 34:8, pages 1341-1356.
Crossref
Crossref
F. G. Holz, K. T. Johnson, U. Bauer-Steinhusen, C. Rech, T. Machewitz, S. Müller & R. P. Finger. (2019) ANDROMEDA – Eine Untersuchung von Einflussfaktoren auf die Adhärenz von Patienten mit neovaskulärer altersabhängiger Makuladegeneration mithilfe des neu konzipierten Patientenfragebogens LAF-IVTANDROMEDA—an investigation of factors influencing the adherence of patients with neovascular age-related macular degeneration using the newly developed patient questionnaire LAF-IVT. Der Ophthalmologe 117:8, pages 765-774.
Crossref
Crossref
Quan Dong Nguyen, Arup Das, Diana V. Do, Pravin U. Dugel, Andre Gomes, Frank G. Holz, Adrian Koh, Carolyn K. Pan, Yasir J. Sepah, Nikhil Patel, Heather MacLeod & Patrik Maurer. (2020) Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology 127:7, pages 963-976.
Crossref
Crossref
Masahito Ohji, Paolo Lanzetta, Jean-Francois Korobelnik, Piotr Wojciechowski, Vanessa Taieb, Celine Deschaseaux, Daniel Janer & Claudia Tuckmantel. (2020) Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison. Advances in Therapy 37:5, pages 2184-2198.
Crossref
Crossref
. (2020) Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen MakulaödemsStatement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema. Der Ophthalmologe 117:3, pages 218-247.
Crossref
Crossref
P.V. Muñoz-Ramón, P. Hernández Martínez & F.J. Muñoz-Negrete. (2020) New therapeutic targets in the treatment of age-related macular degeneration. Archivos de la Sociedad Española de Oftalmología (English Edition) 95:2, pages 75-83.
Crossref
Crossref
P.V. Muñoz-Ramón, P. Hernández Martínez & F.J. Muñoz-Negrete. (2020) Nuevas dianas terapéuticas en el tratamiento de la degeneración macular asociada a la edad. Archivos de la Sociedad Española de Oftalmología 95:2, pages 75-83.
Crossref
Crossref
Robin D. Hamilton, Andreas Clemens, Angelo Maria Minnella, Timothy Y. Y. Lai, Hong Dai, Taiji Sakamoto, Chui Ming Gemmy Cheung, Nor Fariza Ngah, Cornelia Dunger-Baldauf & Frank G. Holz. (2020) Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. PLOS ONE 15:1, pages e0227557.
Crossref
Crossref
Aditya Kelkar, Caroll Webers, Rohit Shetty, Jai Kelkar, Nikhil Labhsetwar, Abhishek Pandit, Madhulika Malode & Sayali Tidke. (2020) Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian Journal of Ophthalmology 68:10, pages 2143.
Crossref
Crossref
Sara Vaz-Pereira, João Paulo Castro-de-Sousa, David Martins, Joaquim Prates Canelas, Pedro Reis, António Sampaio, Helena Urbano, Paulo Kaku, João Nascimento & Carlos Marques-Neves. (2020) The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Ophthalmic Research 63:2, pages 114-121.
Crossref
Crossref
Pan Long, Weiming Yan, Mengshan He, Qianli Zhang, Zhe Wang, Manhong Li, Junhui Xue, Tao Chen, Jing An & Zuoming Zhang. (2019) Protective effects of hydrogen gas in a rat model of branch retinal vein occlusion via decreasing VEGF-α expression. BMC Ophthalmology 19:1.
Crossref
Crossref
Dong-Geun Park, Gahyung Ryu & Min Sagong. (2019) Comparison of Dexamethasone Implant Followed by Bevacizumab versus Bevacizumab Monotherapy for Diabetic Macular Edema. Journal of Retina 4:2, pages 84-92.
Crossref
Crossref
Whitney Shatz, Philip E. Hass, Nikhil Peer, Maciej T. Paluch, Craig Blanchette, Guanghui Han, Wendy Sandoval, Ashley Morando, Kelly M. Loyet, Vladimir Bantseev, Helen Booler, Susan Crowell, Amrita Kamath, Justin M. Scheer & Robert F. Kelley. (2019) Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. PLOS ONE 14:6, pages e0218613.
Crossref
Crossref
Thomas Wecker, Bastian Grundel, Sabine Reichl, Milena Stech, Clemens Lange, Hansjürgen Agostini, Daniel Böhringer & Andreas Stahl. (2019) Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Scientific Reports 9:1.
Crossref
Crossref
Thomas A. Ciulla, Peter Bracha, John Pollack & David F. Williams. (2018) Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. Ophthalmology Retina 2:12, pages 1179-1187.
Crossref
Crossref
Focke Ziemssen, Joachim Wachtlin, Laura Kuehlewein, Maria-Andreea Gamulescu, Thomas Bertelmann, Nikolaus Feucht, Jessica Voegeler, Mirja Koch, Sandra Liakopoulos, Steffen Schmitz-Valckenberg & Georg Spital. (2018) Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany. Diabetes Therapy 9:6, pages 2271-2289.
Crossref
Crossref